• news.cision.com/
  • Bioretec/
  • New shares of Bioretec Ltd subscribed with option rights have been registered with the trade register
English

New shares of Bioretec Ltd subscribed with option rights have been registered with the trade register

Report this content

Bioretec Ltd Company announcement 26 April 2023 at 9.30 a.m. EEST

An aggregate number of 25,000 new shares of Bioretec Ltd have been subscribed for with option rights under option program 2018-1A. The new shares have on 25 April 2023 been registered with the trade register maintained by the Finnish Patent and Registration Office. The total subscription price of EUR 37,500.00 will be recorded in Bioretec's reserve of invested unrestricted equity, and the company's share capital remains unchanged.

Following the registration of the new shares, the total number of shares in Bioretec is 14,136,858.

The new shares will be issued in the book-entry system on or about today 26 April 2023. The new shares will confer shareholder rights in the company as of their registration on the investors' book-entry accounts. Trading in the new shares is expected to commence on Nasdaq First North Growth Market Finland on or about 27 April 2023.

Further enquiries

Timo Lehtonen, CEO, +358 50 433 8493
Johanna Salko, CFO, +358 40 754 8172

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioabsorbable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioabsorbable materials for enhanced surgical outcomes. The RemeOs™ implants are resorbed and replaced by bone, eliminating the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. during March 2023, and CE-mark is expected to receive in Europe during 2023. Bioretec is positioning itself to enter the addressable over USD 7 billion global orthopedic trauma market and to become a game changer in surgical possibilities.

Better healing – Better life. www.bioretec.com

Subscribe